Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer - Phillip Koo

In this 5 for 5 Hot Topics, Phillip Koo, MD. presents the clinical background of Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer, the first FDA-approved F18 PET Imaging Agent indicated in for use in patients with suspected recurrent prostate cancer.  Dr. Koo discusses its use for men with suspected prostate cancer recurrence based on elevated PSA levels following prior treatment. The products safety, efficacy, and good inter-reader variability, as well as the adverse reactions including injection site pain, redness, and a metallic taste in the mouth.

Biography:

Phillip Koo, MD
 

For More information of F18:

Read about the FDA Approval of Axumin™

Read More on Fluciclovine F 18: Clin Nucl Med. 2015 Aug;40(8):e386-91. doi: 10.1097/RLU.0000000000000849.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe